Antioxidants for male infertility: therapeutic scheme and indications. A retrospective single-center real-life study-Reference-Cited by-同舟云学术

Antioxidants for male infertility: therapeutic scheme and indications. A retrospective single-center real-life study

Published:2023-05-08 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Cannarella Rossella¹^ORCID,Crafa Andrea¹,Kaiyal Raneen Sawaid²,Kuroda Shinnosuke²,Barbagallo Federica¹,Alamo Angela¹,Mongioì Laura M.¹,Sapienza Sabrina¹,Condorelli Rosita A.¹,Vignera Sandro La¹,Calogero Aldo E.¹

Affiliation:

1. University of Catania: Universita degli Studi di Catania

2. Cleveland Clinic Glickman Urological and Kidney Institute

Abstract

Abstract This single-center real-life study was conducted to evaluate the most effective combination of nutraceuticals and the most appropriate indications for the treatment of male infertile patients. Infertile patients aged 20–55 years were treated with a combination of antioxidants (Androlen®) (Group 1), with Androlen® and a mixture of fibrinolytic molecules (Lenidase®) (Group 2), or Androlen® and other molecules different from those used for the patients of the Group 2 (Group 3). Patients were also subdivided according to the presence of varicocele, mild testicular hypotrophy, idiopathic infertility, and chronic male accessory gland infection (MAGI). Forty-three patients were enrolled. In the overall analysis, only progressive motility significantly improved after therapy. Subgroup analysis showed a significant increase in progressive motility, total motile sperm count (TMSC), and in the percentage of alive spermatozoa after treatment in the Group A. Progressive motility improved significantly in patients with varicocele, while the TMSC in patients with varicocele and those with idiopathic. The percentage of alive spermatozoa increased in patients with testicular hypotrophy. Treatment with antioxidants increases progressive sperm motility. The association of fibrinolytic or other nutraceuticals does not improve the efficacy of the treatment with antioxidants alone. The treatment was effective in patients with varicocele or idiopathic infertility.

Publisher

Research Square Platform LLC

Reference53 articles.

1. Agarwal A, Mulgund A, Hamada A, Chyatte MR. A unique view on male infertility around the globe.Reprod Biol Endocrinol2015;13,37.

2. Lanzafame FM, La Vignera S, Vicari E, Calogero AE. Oxidative stress and medical antioxidant treatment in male infertility. Reprod Biomed Online 200919; 638 – 59.

3. Reactive oxygen species as an independent marker of male factor infertility;Agarwal A;Fertil Steril,2006

4. Bykova M, Athayde K, Sharma R, Jha R, Sabanegh E, Agarwal A, Mackenzie-Proctor R, Yazdani A, Stankiewicz MT, Jordan V, Showell MG. Antioxidants for male subfertility. Cochrane Database Syst Rev. 2019;3(3):CD007411.

5. Giacone F, Condorelli RA, Mongioì LM, Bullara V, La Vignera S, Calogero AE, Tremellen K, Miari G, Froiland D. Thompson, J. A randomised control trial examining the effect of anantioxidant (Menevit) on pregnancy outcome during IVF-ICSI treatment. Aust N Z J Obstet Gynaecol 2007; 4,216–21.